Table 2.

Results by study arm.

Poly EPlaceboTotal
(n = 19)(n = 20)(n = 39)P
Baseline ACF number0.38a
N192039
 Mean (SD)12.2 (6.8)11.5 (10.6)11.8 (8.8)
 Median9.08.09.0
 Range(5.0–28.0)(5.0–52.0)(5.0–52.0)
6-month ACF number0.25a
N151732
 Mean (SD)12.7 (10.01)11.5 (12.3)12.1 (11.2)
 Median10.08.09.0
 Range(2.0–44.0)(2.0–53.0)(2.0–53.0)
ACF number percent change0.28a,b
N151732
 Mean (SD)3.7 (49.1)0 (52.7)1.7 (55.9)
 Median0.00.00.0
ACF size percent change0.83a
N151631
 Mean (SD)10.3 (61.1)12.6 (102.8)11.5 (83.9)
 Median0.00.00.0
Adenoma recurrence0.69c
 Missing538
 No10 (71.4%)11 (64.75%)21 (67.7%)
 Yes4 (28.6%)6 (35.3%)10 (32.3%)
Adenoma recurrence (≥5 mm)0.36c
 Missing538
 No14 (100.0%)16 (94.1%)30 (96.8%)
 Yes0 (0.0%)1 (5.9%)1 (3.2%)
Percent total dose received0.14a
N192039
 Mean (SD)83.2 (29.3)91.7 (24.0)87.6 (26.7)
  • aWilcoxon rank-sum test.

  • bOne-sided P value.

  • cχ2 test.